Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
N/A
1(20.0%)
Phase 1
1(20.0%)
5Total
Phase 2(3)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07603193Enrolling By Invitation

Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream

Role: collaborator

NCT03322865Phase 2Active Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

Role: collaborator

NCT03474744Phase 2Active Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Role: collaborator

NCT05646303Phase 2Unknown

Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

Role: collaborator

NCT02948088Completed

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

Role: collaborator

NCT04160130Not ApplicableUnknown

RHEIA (Randomized researcH in womEn All Comers With Aortic Stenosis)

Role: lead

NCT04195373Phase 1Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Role: collaborator

All 7 trials loaded